output
20092022
most citedUse of Non-concurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

35 citations

5 papers

stat.AP2022★ 35 cited

Use of Non-concurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

Rajeshwari Sridhara, Olga Marchenko, Qi Jiang +14

This article summarizes the discussions from the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section Open Forum that took place on December 10, 2020 and was org…

stat.ME2022★ 5 cited

Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the MORPHEUS-UC trial

Guanbo Wang, Melanie Poulin Costello, Herbert Pang +6

Phase Ib/II oncology trials, despite their small sample sizes, aim to provide information for optimal internal company decision-making concerning novel drug development. Hybrid con…

q-bio.QM2019★ 13 cited

A Quantum-Inspired Method for Three-Dimensional Ligand-Based Virtual Screening

Maritza Hernandez, Guo Liang Gan, Kirby Linvill +3

Measuring similarity between molecules is an important part of virtual screening (VS) experiments deployed during the early stages of drug discovery. Most widely used methods for e…

q-bio.QM2017

Small Animal Multivariate Brain Analysis (SAMBA): A High Throughput Pipeline with a Validation Framework

Robert J Anderson, James J Cook, Natalie A Delpratt +6

While many neuroscience questions aim to understand the human brain, much current knowledge has been gained using animal models, which replicate genetic, structural, and connectivi…

stat.AP2009★ 17 cited

A new latent cure rate marker model for survival data

Sungduk Kim, Yingmei Xi, Ming-Hui Chen

To address an important risk classification issue that arises in clinical practice, we propose a new mixture model via latent cure rate markers for survival data with a cure fracti…